Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy (SCS)

This study has been completed.
Information provided by:
Maastricht University Medical Center Identifier:
First received: December 3, 2008
Last updated: July 7, 2010
Last verified: July 2010

Rationale: Diabetic neuropathy is one of the most common complications of Diabetes Mellitis (DM). Pain is a common symptom of diabetic neuropathy, affecting 11-34% of patients suffering form DM. The current available medication often provides insufficient pain relief and/or has unacceptable side effects. Spinal cord stimulation (SCS) has been used for over 30 years to treat neuropathic pain. Various small clinical studies have shown a beneficial effect of SCS on pain in PDP.

Objective: This study is a preparation to a RCT to investigate whether SCS is a good indication in patients which suffer from pain with moderate-to-severe PDP in the lower limbs. The main objective of this study is whether SCS leads to sufficient pain relief and to obtain insight into the working mechanism of SCS. The hypothesis is that the effect SCS is most effective in patients without major sensory deficits. Furthermore, practical feasibility of the test procedures described in the study protocol will be examined, including the questionnaires to be filled out by the patient. Also, technical feasibility of SCS will be investigated. Besides the feasibility, the possibility of predicting successful pain relief by SCS by classifying patients according to the Michigan Diabetic Neuropathy Score will be assessed. Furthermore, possible other predictors for successful pain relief by SCS will be defined. Study design: the study is a pilot study in preparation to a RCT to investigate the effect of spinal cord stimulation on pain in moderate-to-severe PDP patients.

Study population: patients suffering from moderate-to-severe PDP in the lower limbs as diagnosed by clinical symptoms and supported by the Michigan Diabetic Neuropathy Score.

Intervention: patients will receive 2 weeks of trial stimulation and best (drug) treatment as usual.

Main study parameters/endpoints: Main study parameter is the pain score as measured by a numeric rating scale (NRS) according to Jensen and a Patient Global Impression of Change for pain measured on a 7-point Likert scale.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: SCS related risks include: lead migration (14%), lead breakage (7%), implanted pulse generator migration (1%), loss of therapeutic effect, lost or unpleasant paresthesias (12%), infection or wound breakdown (10%), Pain at IPG incision site (12%), IPG pocket fluid collection (5%).

Condition Intervention
Diabetic Neuropathies
Device: spinal cord stimulation

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy (PDP Study) A Pilot Study

Resource links provided by NLM:

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Pain intensity measured on a weighted NRS according to Jensen and a PGIC for pain measured on a 7-point Likert scale. [ Time Frame: Baseline, 2 weeks after trial stimulation, 3, 6 and 12 months ]

Secondary Outcome Measures:
  • The practical- and technical feasibility of the procedures, predicting successful pain relief by SCS by classifying patients according to the MDNS. Define possible other predictors for successful pain relief. [ Time Frame: Baseline, 2 weeks after trial stimulation, 3, 6 and 12 months ]

Enrollment: 15
Study Start Date: January 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: spinal cord stimulation
    The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
    Other Name: Medtronic leads and neurostimulator (CE mark 0123)

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Moderate-to-severe PDP in the lower limbs

    • The pain intended to treat has been present for more than 12 months
    • Previous treatment has been unsuccessful (insufficient pain relief and/or unacceptable side-effects) with drugs from the following drug categories:
    • Amitriptyline or an other tricyclic antidepressant and/or
    • Pregabalin (Lyrica), Gabapentin (Neurontin) or Carbamazepine and/or
    • Duloxetine (Cymbalta) and/or
    • Tramadol or strong opioids Patients were treated with 3 drugs from the above mentioned drug categories and followed the treatment algorithm for painful diabetic polyneuropathy according to Jensen. Each drug is tried for 3 weeks and dose is raised once. By insufficient pain relief and/or unacceptable side-effects, the drug treatment was stopped. Patients reached a steady state in medication use and it is not allowed to change the use of medication during the study.
  • Mean pain intensity should be 5 or higher measured on a numeric rating scale (NRS), which will be scored 3 times per day during 4 days according to Jensen.
  • Patients age is between 18 and 75 years.

Exclusion Criteria:

  • The patient has had neuromodulation therapy during the month before the intake
  • The patient has ever had neuromodulation
  • Neuropathic pain prevalent in the upper limbs (NRS above 3)
  • Neuropathy or chronic pain of other origin than diabetes mellitus (NRS above 3)
  • Addiction: drugs, alcohol (5E/day) and/or medication

    • Drugs: cocaine, heroine, marihuana,
    • Alcohol: wine, beer, liquor.
    • Medication: benzodiazepines, morphine receptor agonists.
  • Insufficient cooperation from the patient (little motivation, understanding or communication)
  • Blood clotting disorder
  • Immune deficiency (HIV-positive, corticosteroids with a dose equivalent to prednisolone 10 mg, immunosuppressive, etc.)
  • Peripheral vascular disease, no palpable peripheral pulsations at the feet (inclusion is possible if pulsations are absent, but ankle/brachial index is between 0.7 and 1.2 in both feet)
  • Active foot ulceration
  • Life expectancy shorter than 1 year
  • Pacemaker
  • Local infection or other skin disorders at site of incision
  • Psychiatric disorders
  • Pregnancy
  • Severe cardiac or pulmonary failure (NYHA classification II or higher)
  • Unstable blood glucose control (change in HbA1c more than 1,0% (absolute value) in three months prior to inclusion)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00802022

Maastricht University Hospital
Maastricht, Limburg, Netherlands, 6229 HX
Sponsors and Collaborators
Maastricht University Medical Center
Principal Investigator: Maarten van Kleef, prof. dr. Maastricht University Hospital
  More Information

Responsible Party: Prof. dr. M. van Kleef, Maastricht University Medical Center Identifier: NCT00802022     History of Changes
Other Study ID Numbers: MEC 08-2-118
Study First Received: December 3, 2008
Last Updated: July 7, 2010

Keywords provided by Maastricht University Medical Center:
diabetic neuropathies
electric stimulation therapy

Additional relevant MeSH terms:
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases processed this record on May 25, 2017